利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

173 条记录 (耗时 0.061 秒)

    VARIANTS OF C-TYPE NATRIURETIC PEPTIDE
    92.
    发明公开
    VARIANTS OF C-TYPE NATRIURETIC PEPTIDE 审中-公开
    变异利钠肽C型

    公开(公告)号：EP2217620A2

    公开(公告)日：2010-08-18

    申请号：EP08851395.7

    申请日：2008-11-21

    申请人： BioMarin Pharmaceutical Inc.

    发明人： WENDT, Dan, J. ,  AOYAGI-SCHARBER, Mika ,  BELL, Sean ,  WEI, Dong ,  KAKKIS, Emil, D. ,  BLIESATH, Joshua, R.

    IPC分类号： C07K14/58 ,  A61K38/22

    CPC分类号： C07K14/58 ,  A61K38/2242 ,  A61K47/60

    摘要： The present invention provides variants of C-type natriuretic peptide (CNP) comprising one or more deletions; additions of and/or substitutions with natural amino acids, unnatural amino acids and/or peptidomimetics (including peptide bond isosteres); amino acid extensions; and/or other chemical moieties such as, e.g., poly(ethylene glycol) and hydrophobic acids. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders such as, e.g., skeletal dysplasias and achondroplasia, and vascular smooth muscle disorders such as, e.g., restenosis and arteriosclerosis.

    USE OF BACTERIAL ENZYMES E.G. HEPARINASES, CHONDROITINASES FOR MODULATING WOUND HEALING PROCESSES
    97.
    发明授权
    USE OF BACTERIAL ENZYMES E.G. HEPARINASES, CHONDROITINASES FOR MODULATING WOUND HEALING PROCESSES 失效
    细菌的使用酶例如 肝素酶CHODROITINASEN伤口愈合过程来调节

    公开(公告)号：EP0769961B1

    公开(公告)日：2006-11-02

    申请号：EP95926645.3

    申请日：1995-07-07

    申请人： Biomarin Pharmaceutical Inc.

    发明人： ZIMMERMANN, Joseph ,  VLODAVSKY, Israel ,  BENNETT, D., Clark ,  DANAGHER, Pamela ,  BROUGHTON, Richard

    IPC分类号： A61K38/51 ,  A61P17/02

    CPC分类号： A61K38/51 ,  Y10S530/825

    摘要： Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors. This is achieved by targeting heparin or heparan sulfate degrading activites to the cell surface. Targeting the heparin degrading activity can be achieved by genetically engineering a ligand binding functionality into the heparinase proteins, or by physically controlling the localized enzyme concentration through the method of administration.